The Aquaro Team

Alberto Elli
CEO

Alberto has spent over 20 years in midsize private and large public companies in different management and executive positions. He built his expertise in a variety of industries: manufacturing, pharmaceutical, medical devices, chemicals and large consumer goods. He is a global strategist with a track record in building fast growing and profitable business through organic growth and business development. Alberto is expert in managing M&A or divestures opportunities: he has directed teams acquiring more than 20 companies (from $5M to $350M) and created a process to fully integrate acquired companies. He has leadership expertise in directing turnarounds, restructuring, liquidity events, exit strategies, and customer relationship issues.

Jack Ball
Executive Chairman

Mr. Ball brings a strong track record of life sciences leadership and a strong background in commercial operations in the life sciences. Currently, he leads Solulink, Inc. as its Chief Executive Officer. Solulink is a life sciences tools company that develops, manufactures, and markets proprietary next generation linking technologies. Mr. Ball is also President of Tyball Associates, LLC, and an Adjunct Professor at the University of Michigan, Ross Business School in Entrepreneurial Studies. Previously, Mr. Ball served as Chief Commercial Officer of Accuri Cytometers, Inc. from the commercialization of its first product through its acquisition by BD Biosciences in 2011. Prior to joining Accuri, he was CEO of Amnis Corporations. Mr. Ball also served as Chief Commercial Officer for Molecular Probes, Inc. (acquired by Life Technologies). Prior to Molecular Probes, Mr. Ball was the Senior VP & General Manager of the Life Sciences Group at Orchid Biosciences, and a senior executive at Amersham Pharmacia Biotech Inc., where he rose to President, North America. Mr. Ball also serves on the board of directors of several life science companies, including Swift Biosciences, ViroCyt, NanoCellect, Wasatch Microfluidics, ENT Biotech Solutions, DNA Software and CelSee Diagnostics, as well as the non-profit organization the Association of Commercial Professionals (ACP-LS).

Collin Rich, Ph.D.
CTO

In addition to co-founding Aquaro Biosystems, Collin’s experience includes launching and managing R&D efforts at five different medical device start-ups over the past 15 years, including as co-founder of Accuri Cytometers, which was ultimately sold to Becton Dickinson. His formal training as an Electrical Engineer is augmented by familiarity with a wide variety of mechanical, fluidic, and other technologies, as well as practical experience managing the fast-paced activity of an aggressive, innovative R&D team. Collin is co-inventor on over 42 U.S. and international patents.

Greg Krueger
Vice President, Sales and Marketing

Greg brings over 20 years of experience in the commercialization of life science products, including sales, marketing and business development roles at Sartorius Stedim Biotech, Becton Dickinson, Accuri Cytometers, GE Healthcare, Pharmacia and Amersham. He obtained his undergraduate and graduate education in science at the University of Wisconsin in Madison, as well as a Masters of Business Administration at the Keller School of Management.

David Mack
Vice President, Customer Support and Service

David has a proven track record of leadership in the life sciences, environmental and chemical industries with over 25 years of experience. For the last 8 years prior to joining Aquaro, he was the Service and Support leader for the Accuri product line and served as Director – Technical Support and Customer Service at Accuri Cytometers, Inc. before its acquisition by BD Biosciences in 2011. Prior to joining Accuri, he held various management positions in technical support and project management for venture and industry backed technology start-ups: Sensicore, Enovis, Neolytica and eChemicals preceded by 10 years of experience in a large commercial environmental laboratory. David brings his current expertise of service strategies and customer service in the life science industry along with strong laboratory operations experience, regulatory and quality knowledge and proven business process development skills.

Gary Hess
Director of Production and Supply Chain

Gary brings twenty eight years of experience as a Printed Circuit Board and mechanical designer. He most recently was a staff electrical/mechanical engineer with Becton Dickinson. Previously, Gary was involved with three Ann Arbor start ups: Irwin Magnetics, Aeroquip Precision Spheres, and Accuri Cytometers. He has management experience in manufacturing and supply chain and has a degree in Business Administration.

Board of Directors

Jack Ball

Mr. Ball brings a strong track record of life sciences leadership and a strong background in commercial operations in the life sciences. Currently, he leads Solulink, Inc. as its Chief Executive Officer. Solulink is a life sciences tools company that develops, manufactures, and markets proprietary next generation linking technologies. Mr. Ball is also President of Tyball Associates, LLC, and an Adjunct Professor at the University of Michigan, Ross Business School in Entrepreneurial Studies. Previously, Mr. Ball served as Chief Commercial Officer of Accuri Cytometers, Inc. from the commercialization of its first product through its acquisition by BD Biosciences in 2011. Prior to joining Accuri, he was CEO of Amnis Corporations. Mr. Ball also served as Chief Commercial Officer for Molecular Probes, Inc. (acquired by Life Technologies). Prior to Molecular Probes, Mr. Ball was the Senior VP & General Manager of the Life Sciences Group at Orchid Biosciences, and a senior executive at Amersham Pharmacia Biotech Inc., where he rose to President, North America. Mr. Ball also serves on the board of directors of several life science companies, including Swift Biosciences, ViroCyt, NanoCellect, Wasatch Microfluidics, ENT Biotech Solutions, DNA Software and CelSee Diagnostics, as well as the non-profit organization the Association of Commercial Professionals (ACP-LS).

Alberto Elli

Alberto has spent over 20 years in midsize private and large public companies in different management and executive positions. He built his expertise in a variety of industries: manufacturing, pharmaceutical, medical devices, chemicals and large consumer goods. He is a global strategist with a track record in building fast growing and profitable business through organic growth and business development. Alberto is expert in managing M&A or divestures opportunities: he has directed teams acquiring more than 20 companies (from $5M to $350M) and created a process to fully integrate acquired companies. He has leadership expertise in directing turnarounds, restructuring, liquidity events, exit strategies, and customer relationship issues.

Thomas A. Raffin, M.D.

Tom spent 24 years on the faculty at Stanford University School of Medicine where he remains the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics, former Chief of Pulmonary and Critical Care Medicine, and Co-Founder and Director Emeritus of the Stanford University Center for Biomedical Ethics. He has written over 200 articles, chapters and books. Over the past two decades he has worked extensively in the healthcare and medical device sectors and is a co-founder of Rigel Pharmaceuticals. Tom has represented THP on the boards of Akoya Biosciences, AngioScore (acquired by Spectranetics), Aquaro, Confirma (acquired by Merge), LDR Spine (NASDAQ:LDRH), PneumRx (acquired by BTG Plc), Freedom Innovations (acquired by Health Evolution Partners) and Magstim. He was an observer on the boards of Estech (acquired by AtriCure) and Vidacare (acquired by Teleflex). Tom received a BA from Stanford University and an M.D. from Stanford University School of Medicine and completed his medical residency at the Peter Bent Brigham Hospital in Boston.

Rob C. Hart, CFA

Rob has worked in the area of securities law, corporate finance, venture capital and mergers & acquisitions since 1998. Prior to joining THP, he worked in Citigroup Global Markets’ San Francisco office focused on healthcare investment banking and acquisition finance. Previously, Rob worked at the Securities & Exchange Commission in Los Angeles and the New York-based law firm of Cravath, Swaine & Moore. Rob also served as a Peace Corps Volunteer in the Dominican Republic. Rob currently represents THP on the boards of Aquaro, MedPricer and TrakCel, and was previously an observer on the board of Freedom Innovations. Rob received a BS in Geological Sciences and a BA in Economics from UCSB. He received a JD/MBA from Northwestern University School of Law and Kellogg School of Management.

Deval A. Lashkari, Ph.D.

Deval has worked in the life sciences area developing and commercializing novel technologies. He gained corporate and business development experience through senior management positions in a number of life science companies. He was a founding Research Director at Synteni, which was acquired by Incyte Genomics, where he became Director of Product Development. He also worked with Operon Technologies (acquired by Qiagen), and Genometrix. Deval has represented THP on the boards of AcroMetrix (acquired by Life Technologies), Active Motif, Agena Bioscience, Althea Technologies (acquired by Ajinomoto), AltheaDx, Applied Precision (acquired by GE), Argonaut, Aurora Discovery (acquired by NEXUS Biosystems), Asuragen, Aquaro, Dynex, NEXUS Biosystems (acquired by Brooks Automation), Precision NanoSystems, RareCyte, Sage Labs (acquired by Horizon Discovery), and SwitchGear Genomics (acquired by Active Motif). He has been an observer on the boards of Akoya Biosciences, Dharmacon (acquired by Fisher Scientific) and Carterra. Deval received a BA from the University of California, Berkeley and a PhD from Stanford University and currently serves on the Stanford Medical School Alumni Board of Governors.
 

Scientific Advisors

 

Duane Newton

Dr. Newton received a B.S. (1988) and Ph.D. (1993) in Biology (1988) from the University of Dayton, Dayton, Ohio. He completed Post-Doctoral training at the University of Tennessee and the VA Medical Center in Memphis, Tennessee from 1993-1998, and a Clinical and Public Health Microbiology Fellowship at the University of Rochester Medical Center, Rochester, New York from 1998-2000. In 2000 he was appointed as Manager of the Virology/Immunology Section of the Department of Community Health, Division of Infectious Diseases, Bureau of Laboratories for the State of Michigan and as Adjunct Assistant Professor for the Michigan State University Medical Technology Program. In 2002, he joined the faculty of the Department of Pathology at the University of Michigan. Currently, Dr. Newton is Director of the Clinical Microbiology Laboratories and Associate Director of Clinical Pathology for Michigan Medicine. He holds appointments as both Professor of Pathology in the University of Michigan Medical and Professor of Epidemiology in the University of Michigan School of Public Health. He received his certification as a Diplomate by the American Board of Medical Microbiology in 2004 and was elected as a Fellow in the Infectious Diseases Society of America in 2015. Dr. Newton has previously served on the Molecular Diagnostics Scientific Advisory Board for Roche Diagnostics, and has also served as a consultant for other diagnostic startup companies.